Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Serelaxin: a novel therapeutic for vascular diseases
Author: Leo, C.H.
Jelinic, M.
Ng, H.H.
Tare, M.
Parry, L.J.
Citation: Trends in Pharmacological Sciences, 2016; 37(6):498-507
Publisher: Elsevier
Issue Date: 2016
ISSN: 0165-6147
Statement of
Chen Huei Leo, Maria Jelinic, Hooi Hooi Ng, MarianneTare, Laura J.Parry
Abstract: Vascular dysfunction is an important hallmark of cardiovascular disease. It is characterized by increased sensitivity to vasoconstrictors, decreases in the endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH). Serelaxin (recombinant human relaxin) has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in acute heart failure. In this review we first describe the contribution of endogenous relaxin to vascular homeostasis. We then provide a comprehensive overview of the novel mechanisms of serelaxin action in blood vessels that differentiate it from other vasodilator drugs and explain how this peptide could be used more widely as a therapeutic to alleviate vascular dysfunction in several cardiovascular diseases.
Keywords: Serelaxin; vascular dysfunction; endothelium; prostanoids; nitric oxide
Rights: © 2016 Published by Elsevier Ltd.
DOI: 10.1016/
Published version:
Appears in Collections:Aurora harvest 4
Pharmacology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.